From 2012 through 2022, China's penicillins and streptomycins bulk market displayed significant variation in market value. After a small decline of 0.73% in 2013, the market experienced robust growth, peaking with a 29.35% increase in 2014. This positive trend continued, culminating in a 92.093 million USD valuation in 2021, marking a 13.59% year-on-year rise. However, 2022 saw a 6.27% decline. On a five-year basis, the Compound Annual Growth Rate (CAGR) was 3.54%, showing moderate steady long-term growth despite fluctuations.
Future trends to watch include impacts from regulatory changes and innovations in antibiotic treatments. Market dynamics might also shift based on global supply chain adjustments and developments in antimicrobial resistance management. Monitoring these factors will be critical for anticipating future market movements.
